CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the c

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price t

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the pric

Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to

HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and rais

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and ra

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers th

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises th

TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price targe

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price ta

It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut

Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript

Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-qua

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pi

Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory ch

Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and su

A quarter-points rate hike has been bandied about as a possibility today.

Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple scl

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the qua

Biogen NASDAQ: BIIB reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year ea

Biogen (NASDAQ:BIIB) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 an

Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus E

Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the pr

Biogen Inc (BIIB) released its 8-K filing on July 29, 2026, indicating notable performance in its re

Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjuste

Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, dr

Biogen's growth portfolio, which includes one closely watched Alzheimer's drug, is a bright spot in

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 result

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors wa

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings

Vitro Diagnostics (OTCMKTS:VODG - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are b

Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price tar

B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers

Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that results from the real-world Lecan

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDA

Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AX

Truist Securities analyst Srikripa Devarakonda upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst rating

Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuti

U.S. stocks bounce sharply on Tuesday as lower Treasury yields and Trump's signals of a potentia

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

U.S. stocks declined, with Dow Jones falling almost 600 points and software stocks dipping for an ei

U.S. stock futures down; AutoNation, Amazon, Philip Morris, Reddit, and Biogen expected to report qu

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr